Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
October 17, 2023 08:00 ET
|
Prime Medicine, Inc.
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
Prime Medicine to Present at Upcoming Investor Conferences
September 19, 2023 08:00 ET
|
Prime Medicine, Inc.
Cambridge, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine to Present at Upcoming Investor Conferences
August 31, 2023 08:00 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 07, 2023 16:01 ET
|
Prime Medicine, Inc.
-- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT...
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome
June 22, 2023 08:00 ET
|
Prime Medicine, Inc.
-- Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform -- -- Aim to reduce toxicity of conditioning...
Prime Medicine to Present at Investor Conferences in June
May 31, 2023 08:00 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine to Present at Virtual Investor Conferences in May
May 17, 2023 16:05 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
May 17, 2023 06:00 ET
|
Prime Medicine, Inc.
Data demonstrated Prime Editors efficiently, reproducibly and durably corrected the causative mutation of CGD, supporting advancement of development candidate PM359 New preclinical data highlighted...
Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates
May 11, 2023 08:00 ET
|
Prime Medicine, Inc.
-- New data further demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting potential of PASSIGE platform to multiplex edit CAR-T cells to be presented at ASGCT...
Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days
March 27, 2023 08:00 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...